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Systemic lupus erythematosus (SLE) has shown an association with high levels of prolactin, low levels of dehydroepiandrosterone
(DHEA), and induction of inflammatory cytokines in the serum of patients with the disease. This preliminary study examined
the relevance of a −1149G/T functional single-nucleotide polymorphism (SNP) (rs1341239) in the promoter of the extrapituitary
prolactin gene in a cohort of African American and European American women with lupus. Examination of this SNP revealed
that the −1149TT genotype was correlated with higher levels of prolactin in serum and prolactin gene expression (p = 0.0001) in
peripheral blood mononuclear cells (PBMCs). Lower levels of DHEA in serum were demonstrated in lupus patients (p = 0.001);
thosewith the−1149TT genotype had the lowest levels ofDHEA. Furthermore, a small subset of womenwhowere onDHEA therapy
and had a TT genotype showed a significant decrease in prolactin gene expression and lower disease activity scores (SLEDAI).
Lupus patients, particularly African Americans, had significantly higher levels of IL-6 (p = 0.0001) and TNF-𝛼 (p = 0.042). This
study suggests that the −1149TT genotype may be a risk factor for lupus and may predict who could possibly benefit from DHEA
therapy; therefore, these results should be validated in a larger cohort with all ethnic groups.
1. Background
Systemic lupus erythematous (SLE) is a complex debili-
tating and fatal autoimmune disease affecting between 1.4
and 2.0 million Americans [1]. Hormonal, infectious, and
environmental factors have been implicated in the etiology
of the disease [2, 3]. Although the precise etiology of SLE
remains elusive, the pathogenesis is often attributed to the
development of antinuclear or anti-double stranded- (ds-)
DNA autoantibodies [2, 4, 5]. Of the three types of lupus
(systemic, discoid, and drug-induced), it is estimated that
70% of diagnosed lupus cases are systemic in which a
major organ is affected in 50% of the cases, whereas discoid
lupus accounts for approximately 10% of all other cases [1].
Genetic susceptibility to lupus has also been demonstrated by
the fact that 20% of people with lupus will have a close relative
(parent or sibling) who already has lupus or may develop
lupus and, furthermore, approximately 5% of the children
born to individuals with lupus will develop the illness [1].
Two noteworthy and perplexing aspects of SLE are its biases
towards women and non-Europeans. SLE exhibits a female
to male bias during prepubescence that increases from 4.5 : 1
in adolescence to 8–12 : 1 in adults and then declines to
2 : 1 in adults >60 years of age [2]. Women of childbearing
age account for approximately 80–90% of SLE patients [6].
African American women experience 2–10-fold increased
risk for developing SLE compared to European American
women, develop symptoms at an earlier age, and have more
severe symptoms and increasedmortality [1, 2, 7, 8]. In fact, as
Hindawi Publishing Corporation
Journal of Immunology Research
Volume 2015, Article ID 435658, 10 pages
http://dx.doi.org/10.1155/2015/435658
2 Journal of Immunology Research
many as 1 in every 250AfricanAmericanwomen is diagnosed
with lupus [9].
Although few biomarkers have been discovered in early
stages of lupus development, a number of biological changes
have been noted in animal models or molecular epidemio-
logical human studies [10]. High levels of prolactin have been
associated with SLE and these levels have been correlated
with a single-nucleotide polymorphism in the promoter of
the prolactin gene [11]. However, a number of studies have
shown conflicting results with this observation, likely due to
different ethnic groups used in the various studies [12, 13].
Prolactin participates in a number of important functions
in the body: it performs as a hormone, mainly due to its
pituitary production, and it acts as a cytokine. It is prolactin’s
role as a cytokine, in which it participates in autocrine and
paracrine actions that suggests an important role in the
immune system. Prolactin is also secreted by immune cells
and its receptor belongs to the family of cytokine receptors
type 1 [14]. Although prolactin expression by the pituitary
and other tissues utilizes the same gene, the promoters,
regulatory regions, transcriptional control mechanisms, and
final mRNA transcripts are tissue-dependent [15]. Studies
have suggested its role in immunomodulation; however,
the actual role of prolactin in the immune system remains
unclear.
In addition to high levels of prolactin, lupus patients
have low serum levels of dehydroepiandrosterone (DHEA).
DHEA and its metabolite, dehydroepiandrosterone sulphate
(DHEAS), are the major androgens secreted by the adrenal
glands and are the precursor for estrogen and testosterone
[16]. DHEA exerts antiproliferative and anti-inflammatory
effects, and it modulates immune function [17]. In addition
to low levels of DHEA in lupus patients, studies have shown
low levels of DHEA in other inflammatory diseases [18].
One of the overall objectives of this study was to
determine if the polymorphism in the promoter of the
extrapituitary prolactin gene modulates expression levels of
prolactin, particularly in African American women whose
inclusion has been limited in other studies, and whether this
polymorphism plays a role in patients’ response to DHEA
therapy. Levels of DHEA, DHEAS, estrogen, and testosterone
in women with and without lupus were examined. Finally,
this study also investigated whether ethnic differences were
noted in IL-6 or TNF-𝛼 levels between European American
women and African American women.
2. Methods
2.1. Human Blood Samples. Blood samples were obtained
and processed as previously published from our laboratory
[19] from a cohort of patients, after obtaining informed
consent, who had been diagnosed with lupus according to
the American College of Rheumatology criteria and were
currently on routine therapy in addition to treatment with
or without DHEA. This study consisted of a total of 256
patients, 87 African American females with lupus, 76 healthy
age-matched controls (will be designated as nonlupus); 25
European American females with lupus, 33 healthy age-
matched controls (will be designated as nonlupus); 10 African
American males with lupus, 13 healthy age-matched controls
(will be designated as nonlupus); and 5 European American
males with lupus, 7 age-matched healthy controls (will be
designated as nonlupus).These patients were a part of a larger
LUPUS study at the Brody School of Medicine-East Carolina
University, Greenville, NC. For consistency, all blood samples
were obtained between 9:00 am and 12:00 pm,with a previous
period of fasting and resting. Whole blood was collected in
two portions: 10mL whole blood was collected in plain or
serum separator tubes for serumhormone and cytokine anal-
yses and an additional 10mL whole blood was collected in
heparinized tubes formolecular biological studies. Blood and
serum samples were shipped after collection to the National
Center for Toxicological Research (NCTR) for molecular and
clinical chemistry analyses. This study received IRB approval
from East Carolina Brody School of Medicine and the FDA
Research Involving Human Subject Committee (RIHSC).
2.2. Prolactin T→G−1149 Polymorphism. Genotyping was
conducted using restriction fragment length polymorphism
(RFLP) analyses and confirmed byDNAsequencing.Genomic
DNA was isolated from peripheral blood mononuclear cells
(PBMCs) using a modified QIAmp DNA Blood Maxi kit
(QIAGEN, Valencia, CA). The polymorphism at position
−1149 of the promoter of the extrapituitary PRL gene was
amplified with the following primers: F-GAAGTTGAG-
CCTCAGGATGG and R-CTCAACAGCTTCTCAGTCA-
ACA. PCR-RFLP analysis with ApoI digestion was con-
ducted on the sequence for prolactin (GENBANK Accession
numberAF068856:GATAACCTGGAGAAAGGAGGAAA-
GATAATTTTATGGAGTT AGAGAGACA) that contained
the prolactin polymorphism in the promoter region. All
polymorphisms were confirmed with automatic sequencing.
2.3. RNA Isolation and Quantitative Real Time PCR. RNA
was extracted as described previously [18] by using a PAXgene
RNA kit (QIAGEN, Valencia, CA). After extraction, all RNA
samples were tested for their integrity and concentration
using a Bio-Rad Experion Automated Electrophoresis Sys-
tem (BIO-RAD, Hercules, CA). cDNAs were synthesized
from total RNA extractions using a Clontech Advantage
RT-for-PCR Kit (Clontech, Mountain View, CA). Prolactin
expression analysis was conducted using a Bio-Rad IQ5
quantitative Real Time PolymeraseChainReactionDetection
System (BIO-RAD, Hercules, CA). GAPDH was used as an
endogenous control. qRT-PCR conditions were as follows:
50∘C for 2 minutes and 95∘C for 10 minutes (95∘C for 15
seconds, 62∘C for 30 seconds, and 72∘C for 30 seconds) for 47
cycles. Relative quantitation of prolactin and TNF-𝛼 mRNA
expression was normalized to GADPH and fold changes were
calculated using the 2−ΔΔCT method. Primers utilized for
prolactin, TNF-𝛼, and GAPDH are listed below:
Prolactin R: 5󸀠 CGG CGC GGT CAA ACA GGT CT
3󸀠.
Prolactin F: 5󸀠 ACCAGGAAAAGGGAAACGAAT
GCC 3.
GAPDH-F: 5󸀠 CCACCCATGGCAAATTCCATG 3󸀠.
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Figure 1: SLE disease activity index (SLEDAI) by population. African American (AAF-L) and European American (EAF-L) women with
lupus have the highest SLEDAI scores compared to African American and European American men with lupus.
GAPDH-R: 5󸀠 TCTAGACGGCAGGTCAGGTCC
3󸀠TNF-alpha.
TNF-𝛼-F: 5󸀠-CTT CTC CTT CCT GAT CGT GG-3󸀠.
TNF-𝛼-R: 5󸀠-GCT GGT TAT CTC TCA GCT CCA-
3󸀠.
2.4. Circulating Hormones and Cytokines. Testosterone,
estradiol, prolactin, and DHEA-sulfate were assayed using
Siemens RIA “Coat-A-Count” methods (Los Angeles,
CA) and DHEA was assayed with Diagnostics Systems
Laboratories (Webster, TX) using a coated tube RIA method.
All tubes were counted on a PerkinElmer Cobra 5005 gamma
counter (Shelton, CT). TNF alpha and IFN gamma were
assayed using Antigenix America (Huntington Sta., NY)
ELISA kits. All plates were read on the BioTex Instruments
(Winooski, VT) Elx808 plate reader using Gen5 software for
curve analysis and calculations.
2.5. Statistics. Differences in the frequencies of the GG, GT,
and TT genotypes were analyzed using Fisher’s exact test.
For this study, a comparison analysis was conducted for each
of the specific genes, serum levels, and cytokine profiles.
The comparisons included patients with SLE compared to
the control population and African Americans with SLE
compared to European Americans with SLE. A two-tailed
Mann-Whitney 𝑡-test was used to determine if significant
differences existed. To compare values,𝑝 values of <0.05 were
considered significant. All analyses were performed using
GraphPad Prism (version 4) software (La Jolla, CA).
3. Results
Figure 1 shows the individual differences in the SLEDAI score
by subpopulations in this study.
The highest disease activity within our study was found
in African American and European American women with
lupus. This study had a higher number of African American
women compared to other published studies investigating
the −1149G/T polymorphism. Higher levels of prolactin
were noted in the serum of lupus patients (𝑝 = 0.0026)
(Figure 2(a)). Prolactin gene expression levels were also
higher in PBMCs from lupus patients (𝑝 = 0.0017) compared
to nonlupus controls (Figure 2(b)).
Figure 3 shows a representative electrophoretic gel
depicting RFLP analysis of the prolactin −1149 SNP.
Figure 4(a) shows that the genotype −1149TT was corre-
lated with higher prolactin gene expression (𝑝 = 0.0485) in
lupus (L) patients compared to age-matched nonlupus (NL)
patients. An increase in prolactin levels was also noted in
the serum prolactin protein (𝑝 = 0.0230) of these patients
(Figure 4(b)). However, the −1149GT (𝑝 = 0.1503) and
−1149GG (𝑝 = 0.1480) genotypes did not significantly
correlate to any differences in prolactin gene expression
levels in PBMCs from lupus patients when compared to age-
matched nonlupus patients (Figures 4(c) and 4(d)).
In addition to high levels of prolactin, low levels of DHEA
were detected in the serum of lupus patients. Patients with
lupus had lower levels of DHEA when compared to age-
matched controls (𝑝 = 0.0001) (Figure 5(a)). Lupus patients
with the TT genotype had lower serum levels of DHEA than
patients with the GG genotype (𝑝 = 0.0367) (Figure 5(b)).
Furthermore, African American women with lupus with the
TT genotype had significantly lower DHEA levels (𝑝 =
0.0151), when compared to female African American lupus
patients with the GG or GT genotype (Figure 5(c)) or when
compared to age-matched controls (𝑝 = 0.022) (Figure 5(d)).
When DHEA was given as therapy, patients had a lower
disease activity index (𝑝 = 0.0144) (Figure 6(a)) and those
with theTT genotype had an even lower disease activity index
(𝑝 = 0.0005) compared to the GG genotype (Figure 6(b)). In
addition, DHEA lowered the levels of prolactin in a selected
group of patients (data not shown).
DHEA is thought to regulate proinflammatory cytokines;
therefore, low DHEA levels could play a role in expression
of high levels of cytokines, such as IL-6 and TNF-𝛼. Our data
showed (Figure 7(a)) higher levels of IL-6 expression in lupus
patients (𝑝 = 0.0001) and that African American women
with lupus hadhigher levels thanEuropeanAmericanwomen
(𝑝 = 0.0272) (Figure 7(b)).
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Figure 2: Prolactin expression and serum levels. Patients with lupus have significantly higher serum levels of prolactin (𝑝 = 0.0026) and
expression at the mRNA level in PBMCs (𝑝 = 0.0017), although individual differences are shown among the patients.
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Figure 3: Restriction fragment length polymorphism (RFLP) of prolactin −1149. RFLP analysis with ApoI digestion yields three fragment
lengths to distinguish the three genotypes, GG, GT, and TT.
African American women with lupus also had a higher
level of TNF-𝛼 (𝑝 = 0.0427) (Figure 8).
In addition to high levels of prolactin and low levels of
DHEA, results from this study revealed a significant increase
in serum estradiol in lupus patients (Figure 9(a)) (𝑝 =
0.0003). There was a significant difference in estradiol levels
in premenopausal (female young (FY)) (<50 years of age) and
postmenopausal women (female old (FO)) (>50 years of age)
(𝑝 < 0.05) when compared to their nonlupus counterpart at
eachmenopausal status (𝑝 < 0.05), respectively (Figure 9(b)).
Figure 9(c) further showed that lupus women with the TT
genotype have a significant higher level of estradiol (𝑝 =
0.0001) when compared to the GG genotype. There was no
difference in estradiol levels in lupus males compared to
nonlupus males (data not shown).
No significant differences were found in testosterone
levels between African Americanmales and EuropeanAmer-
ican males with lupus (𝑝 = 0.7639) (Figure 10(a)); however,
a small number of young women with lupus demonstrated
higher levels of testosterone (Figure 10(b)).
4. Discussion
Prolactin’s role in human autoimmune diseases remains a
largely unexplored area in which research is greatly needed,
particularly when investigating whether its involvement in
different ethnic groups may cause different biological out-
comes based on an individual’s exposure and lifestyle factors.
Prolactin’s exact role in the physiology and pathogenesis of
autoimmune diseases, such as lupus, has not been totally
clarified. This protein acts as both a hormone and a cytokine
depending on its biological context [14]. Prolactin is consid-
ered a cytokine due to its secretion by immune cells and by the
fact that its receptors belong to a family of cytokine receptors
type I.
Although prolactin is mainly expressed by the pituitary
gland, extrapituitary promoter expression has been shown
in a number of other organs [20]. Both pituitary and
extrapituitary prolactin share the same gene but are under
different promoters. Extrapituitary expression of prolactin
is cell-specific and is independent of the Pit-1 transcrip-
tion factor, which induces pituitary expression of prolactin
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Figure 4:The genotype TT prolactin levels and expression. A significant number of lupus patients with the TT genotype demonstrated higher
levels of prolactin expression (a) (𝑝 = 0.0485) and protein serum levels (b) (𝑝 = 0.0230). There were no significant differences in expression
or serum levels in the other genotypes GT (c) and GG (d).
[21]. The extrapituitary promoter has been shown to con-
tain a functional single-nucleotide polymorphism (SNP) at
−1149G/T (rs1341239) in the GATA sequence. Studies have
shown that the G allele leads to higher prolactin levels
in lymphocytes in serum [22] and the GG genotype was
associated with systemic lupus [23]; however, our study
showed a different finding. The TT genotype was associated
with higher expression of prolactin in lupus patients which
may be due to the majority demographic in this study being
African American women. Previous studies were done in
different ethnic groups or had a very limited number of
African American women while our study population was
predominantly African American women.
This study further demonstrated that the lupus cohort
in this study had a higher serum level of prolactin in their
PBMCs in comparison to age-matched nonlupus patients.
Not only was the TT genotype associated with higher
expression of prolactin, but also these patients showed
decreased levels of DHEA. DHEA and its metabolite dehy-
droepiandrosterone sulfate (DHEAS) are the most abundant
circulating human adrenal steroids [16]. The critical role
of low levels of DHEA in autoimmune diseases, such as
lupus, rheumatoid arthritis, and other inflammatory diseases,
remains an underexplored area of research; however, studies
have indicated its involvement in improving overall immune
function [24]. Animal studies have shown that high levels
of proinflammatory cytokines, such as IL-6 and TNF-𝛼, are
restored to normal levels by DHEA administration [25]. It
is believed that DHEA decreases TNF𝛼 and IL-6 through
inhibition of NF-𝜅B activation [26]. Higher levels of serum
IL-6 were found in lupus patients in this study, and African
American women had the highest level when compared to
European American women and males. African American
women also had the highest level of TNF-𝛼 when compared
to nonlupus and lupus European American women and
men in general. This study showed that, in a subgroup of
women on DHEA therapy, those lupus patients with the TT
genotype had lower levels of IL-6 expression compared to
those patients on DHEA therapy with GG or GT genotypes.
Furthermore, women with a TT genotype on DHEA therapy
had a lower disease activity score. These results need further
investigation with larger populations; however, they could
explain the conflicting results shown in a number of studies
or clinical trials using prasterone (DHEA) [27–29].
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Figure 5: Serum levels of DHEA. (a) shows that lupus patients had a significant lower level of serum DHEA (𝑝 = 0.0001). (b) shows that the
TT genotype had the lowest level of DHEA compared to GT or GG in lupus patients. Furthermore, (c) demonstrates that African American
women with lupus and the TT genotype had the lowest level of DHEA. (d) shows that the serum DHEA level in TT genotype in African
American women was significantly lower when compared to their normal age-matched nonlupus patients (𝑝 = 0.022).
Lupus patients
SL
ED
A
I s
co
re
0
10
20
30
−DHEA +DHEA
p = 0.0144
(a)
SL
ED
A
I s
co
re
0
2
6
4
10
8
GG GT TT
Genotypes
p = 0.0005
p = 0.1084
(b)
Figure 6: SLEDAI score and DHEA therapy. (a) shows that lupus patients on DHEA therapy had lower SLEDAI scores than patients not on
therapy. (b) demonstrate that those lupus patients with a TT genotype and on DHEA therapy had lower disease activity scores compared to
those with GT and GG genotypes.
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Figure 7: IL-6 serum levels in lupus and nonlupus patients. (a) shows that lupus patients have a significantly higher level of IL-6 compared to
age-matched controls (𝑝 = 0.0001); however, (b) African American women with lupus have an increased level of IL-6 compared to European
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Figure 8: Tumor necrosis factor-alpha (TNF-𝛼) serum levels. African American women with lupus (AAL) had the highest level of TNF-𝛼
compared to European American women with lupus (𝑝 = 0.0427).
This investigation has confirmed earlier reports of low
levels of DHEA in lupus patients and high levels of prolactin.
This study is the first to demonstrate a correlation between
low levels of DHEA and high levels of prolactin and the
TT genotype, particularly in African American women. A
number of other studies that examined the extrapituitary
polymorphism at −1149 showed that the GT was correlated
with high levels of prolactin; however, those studies were
done in populations other than African American women.
Another finding in this study was that high levels of estradiol
were also associated with the TT genotype and lupus patients
in general had a higher level of estrogen when compared to
their nonlupus counterparts, regardless of their menopausal
status.
These findings in African Americans may give valuable
insights into the lack of positive outcomes from various treat-
ments and increased morality rates at younger ages. IL-6 and
TNF-𝛼 expression levels were significantly higher in African
American women. High levels of IL-6 have been associated
with kidney damage in humans and in a number of animal
models [30]. SLE is a chronic inflammatory disease that may
affect any organ system in the body but it is the leading cause
of kidney disease associated with death in young women [31].
IL-6 has both pro- and anti-inflammatory properties and
increased IL-6 expression is a common response to tissue
injury and organ failure [32]. Although this pathway has been
targeted for novel therapeutic approaches,most drugs fail due
to toxicity or other severe side effects.
These results warrant larger studies with diverse popu-
lations to fully understand the role of the functional single-
nucleotide polymorphism −1149G/T in the promoter of the
extrapituitary prolactin gene and its effects on autoimmunity.
Also this study demonstrates that further studies should
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Figure 10: Testosterone levels in serum. (a) No difference was found in testosterone between the small numbers of males with lupus in this
study; however, we did notice a higher level of testosterone in a small number of women less than fifty years of age.
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be conducted on the mechanisms by which DHEA ther-
apy is decreasing disease activity indexes in selected lupus
patient with the TT genotype. Furthermore, more research is
needed to determine if genotypes of prolactin extrapituitary
promoter can be translated into clinical benefit, using a
personalized medicine approach, for patients identification
for DHEA therapy.
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